• Karyopharm published Phase 3 SENTRY trial results evaluating selinexor with ruxolitinib in JAK inhibitor-naïve myelofibrosis.
• Combination delivered rapid, deeper, sustained spleen volume reduction versus ruxolitinib alone, with consistent effects across subgroups.
• Symptom improvement was similar between arms, with meaningful reductions from baseline.
• Overall survival signal reported; spleen volume reduction linked with improved survival.
• Safety described as manageable, consistent with known profiles of both drugs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief on June 14, 2026, and is solely responsible for the information contained therein.